Third Dose of Pfizer-BioNTech Vaccine Approved

European union(EU) drug regulator European Medicines Agency (EMA); new type COVID-19 in the fight against the disease Pfizer-BioNTechvaccine developed by third dosegave the green light to the application of flour on adults.

According to the statements made by the European Medicines Agency, studies on individuals between the ages of 18 and 55 show that a third dose increases the antibody level in the person. strengthens immunity proved. The agency recommends that healthy adult individuals administer a third dose of Pfizer-BioNTech vaccine over the second dose. provided that 6 months have passed He said it could be shot as reinforcements.

Studies on possible side effects of a third dose are ongoing:

EMA also includes Moderna and Pfizer-BioNTech’s mRNA technologyThe third dose of the booster dose of the vaccines he developed with the help of 28 days later He explained that it can also be given to people whose immunity has dropped too much. In addition, it is possible, albeit very rare, negative side effectsIt was noted that there is not enough data yet on how it can create effects after the third dose, and research on this subject continues.

from the EU in December 2020 and January 2021, respectively. ‘safe and effective’ receiving a passing grade Pfizer-BioNTech and modern vaccine; Currently, it is administered to individuals over the age of 12 in EU countries as two doses.

Countries that are members of the European Union, where the decisions of EMA are advisory; Apps are also free to make their own decisions. The third dose of the vaccine, currently developed by Pfizer-BioNTech, for different reasons Applied to immunocompromised persons.